Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020112966 - THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA USING DEVIMISTAT

Publication Number WO/2020/112966
Publication Date 04.06.2020
International Application No. PCT/US2019/063553
International Filing Date 27.11.2019
IPC
A61K 31/20 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/7068 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/704 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
704attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61P 35/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
CPC
A61K 2300/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
2300Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
A61K 31/136
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
136having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/137
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine ; or methadone
A61K 31/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
Applicants
  • RAFAEL PHARMACEUTICALS, INC. [US]/[US]
Inventors
  • LUTHER, Sanjeev
  • PARDEE, Timothy S.
  • CORTES, Jorge E.
Agents
  • DAVIS, Chad E.
  • REID, Andrea L.C.
  • NIHAN, Danielle M.
  • WANG, Gang
  • OH, Euk Charlie
  • STEVENSON, Christian
  • FLEMING, Paul R.
  • ARICO, Joseph W.
Priority Data
62/773,48330.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA USING DEVIMISTAT
(FR) PROCÉDÉS ET COMPOSITIONS THÉRAPEUTIQUES POUR TRAITER LA LEUCÉMIE MYÉLOÏDE AIGUË EN UTILISANT DU DEVIMISTAT
Abstract
(EN)
The invention provides methods, compositions, and medical kits for treating acute myeloid leukemia using devimistat in combination with cytarabine and mitoxantrone. The claims are directed to methods for treating acute myeloid leukemia in a patient comprising administration of devimistat, cytarabine and mitoxantrone pursuant to an induction cycle of 14 days. The induction cycle comprises: devimistat administered as a single daily dose of 2000 mg/m2 on days 1, 2, 3, 4 and 5; cytarabine administered in five doses of about 1.0 g/m2 each every 12 hours beginning on day 3; and mitoxantrone administered as a single daily dose of about 6 mg/m2 on days 3, 4 and 5.
(FR)
L'invention concerne des procédés, des compositions et des trousses thérapeutiques pour le traitement de la leucémie myéloïde aiguë à l'aide de dévimistat en combinaison avec de la cytarabine et de la mitoxantrone. Les revendications concernent des procédés de traitement de la leucémie myéloïde aiguë chez un patient comprenant l'administration de dévimistat, de cytarabine et de mitoxantrone conformément à un cycle d'induction de 14 jours. Le cycle d'induction comprend : du dévimistat administré sous la forme d'une seule dose quotidienne de 2000 mg/m2 aux jours 1, 2, 3, 4 et 5 ; de la cytarabine administrée en cinq doses d'environ 1,0 g/m2 chacune toutes les 12 heures commençant au jour 3 ; et de la mitoxantrone administrée sous la forme d'une dose quotidienne unique d'environ 6 mg/m2 aux jours 3, 4 et 5.
Latest bibliographic data on file with the International Bureau